Emerging targeted therapies, including ASOs, siRNA, ANGPTL3 inhibitors, and FGF-21 analogs, have achieved reductions in triglyceride levels of up to 80% in clinical trials.
Do emerging pharmacological therapies reduce triglyceride levels in patients with severe and refractory hypertriglyceridemia?
Emerging targeted therapies against ApoC-III, ANGPTL3, and FGF-21 show promising efficacy in reducing triglyceride levels by up to 80% in patients with hypertriglyceridemia.
Hypertriglyceridemia is a well-recognized contributor to residual atherosclerotic cardiovascular disease risk and a predisposing factor for acute pancreatitis. Despite the availability of currently available pharmacologic agents and lifestyle interventions, patients with severe and refractory hypertriglyceridemia often fail to achieve adequate control. Recent advances in the molecular understanding of triglyceride metabolism have driven the development of targeted therapies that selectively modulate key regulatory pathways. This study sought to provide an overview of triglyceride regulation, the atherogenic role of remnant lipoproteins, and clinical evidence of emerging triglyceride-lowering therapies. Lipoprotein metabolism is regulated by a complex network of regulatory proteins that include lipoprotein lipase (LPL), apolipoproteins such as apolipoprotein C-III (ApoC-III), and angiopoietin-like proteins (ANGPTLs). Targeting these proteins in the metabolic cascade has shown promising results in reducing triglyceride levels. Emerging therapies such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) directed against ApoC-III (volanesorsen, olezarsen, and plozasiran), inhibitors of ANGPTL3 (evinacumab and zodasiran), and fibroblast growth factor 21 (FGF-21) analogs (pegozafermin) have demonstrated substantial triglyceride-lowering efficacy. These agents have achieved reductions in triglyceride levels of up to 80 percent in clinical trials. Additionally, preliminary evidence suggests that these agents may also reduce the incidence of acute pancreatitis and improve cardiometabolic risk profiles, although dedicated trials are still needed to confirm these outcomes. The therapeutic landscape for hypertriglyceridemia is rapidly evolving. Integrating these novel agents into clinical practice will require individualized treatment plans, sustained lifestyle modification, and careful safety monitoring.
Ibrahim S. Alhomoud (2026) conducted a review in Hypertriglyceridemia. Emerging triglyceride-lowering therapies was evaluated on Triglyceride levels. Emerging targeted therapies, including ASOs, siRNA, ANGPTL3 inhibitors, and FGF-21 analogs, have achieved reductions in triglyceride levels of up to 80% in clinical trials.